Japan· JP-4411001F1040
ジフェンヒドラミン塩酸塩
A diphenhydramine product containing ジフェンヒドラミン塩酸塩, registered in Japan by 興和, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Diphenhydramine is registered in 12 of 19 countries.
Countries holding a registration under ATC R06AA02 (diphenhydramine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 6 of them publish a price we can compare per daily dose
Diphenhydramine · ATC R06AA02
12 / 19 countries
- Belgiumprice
- Canada
- Denmark
- Germany
- Icelandprice
- Ireland
- Japan
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ジフェンヒドラミン塩酸塩
- Manufacturer
- 興和
- Country
- Japan (JP)
- ATC code
- R06AA02
- ATC class
- Diphenhydramine
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
469 interactions on record for diphenhydramine.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Diphenhydramine · interactions on record
469 records
- 14 severe
- 417 moderate
- 2 minor
Most severe, free to view
- Potassium chlorideA12BA01severe
- Potassium citrateA12BA02severe
- EliglustatA16AX10severe
- Potassium chlorideB05XA01severe
36 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under R06AA02
Diphenhydramine, as other registers publish it.
- United StatesAdult Allergy ReliefCalmCo
- United StatesAdult Allergy ReliefWALGREEN COMPANY
- United KingdomAdult Meltus Night Time syrupSSL International Plc
- United StatesADWE dye-free childrens allergyRARITAN PHARMACEUTICALS INC
- United StatesADWE dye-free childrens allergyRARITAN PHARMACEUTICALS INC
- United StatesAller-BenSam's West Inc
- United StatesAllergiesUnconditional Love
- United StatesallergyMeijer Distribution Inc
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d94653d2-8085-41dc-ae39-72a2bcb96c1f GET /v1/drugs/d94653d2-8085-41dc-ae39-72a2bcb96c1f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１０ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4411001F1040",
"category": "内用薬",
"price_yen": 6.3,
"generic_name": "ジフェンヒドラミン塩酸塩",
"product_name_jp": null,
"therapeutic_class": "4411",
"transitional_expiry": null
}See everything about diphenhydramine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.